LegoChem Bioscience announced on the 22nd that it has received approval from the US Food and Drug Administration (FDA) for a phase 1/2 clinical trial plan (IND) for 'LCB84' targeting various solid cancers such as triple-negative breast cancer and colorectal cancer. It submitted a clinical trial protocol to the FDA in May and obtained plan approval within a month.

This clinical trial will be conducted in the United States and Canada for about 300 patients with advanced solid cancer. The safety and tolerability of LCB84 monotherapy and immuno-oncology combination therapy will be evaluated. The phase 1 dose-escalation trial is conducted in up to eight institutions. The phase 2 clinical trial (Dose Expansio